TRPT1

Across TCGA pan-cancer cohorts, TRPT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRPT1 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRPT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRPT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where TRPT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	1.000	0.537	.008	18	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	17	view →
LSCC	OS	Tertile	III,IV	0.497	0.918	.011	15	view →
LUAD	OS	Median	III,IV	0.301	0.725	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRPT1–PDAC (OS)

Open the PDAC breakdown →